Accelerating world class research in Liverpool
A £11.5m loan to a world class life science hub in Liverpool marked a key milestone for the Chrysalis Fund. Not only was it the largest commitment made by the fund to date, but it also enabled a new chapter in the city’s history – the opportunity to lead the global fight in antibiotic resistance.
The new £25m Liverpool Life Sciences Accelerator co-locates the Royal Liverpool and Broadgreen University Hospitals NHS Trust, the Liverpool School of Tropical Medicine (LSTM) and a raft of relevant SMEs for large scale industrial collaboration and product development partnerships.
Liverpool Life Sciences Accelerator
Forming a key part of Liverpool’s growing Knowledge Quarter, Liverpool Life Sciences Accelerator will be a 70,000 square foot facility providing state-of-the-art laboratory space, offices and amenities. Situated on Daulby Street, within the grounds of the Royal Liverpool University Hospital, it will provide a hub for life sciences, enabling clinicians, academics and industry to collaborate in research and innovation to develop their ideas into the life-saving treatments. Two floors will also be devoted to LSTM’s Resistance mitigation portfolio, which is playing a leading role in the global fight against the growing threat of antibiotic resistance.
Building on site started in December with the Life Sciences Accelerator due to open in June 2017.
Driving forwards a new health campus in Liverpool
Helen Jackson, director of strategy and transformation at the Trust, said: “The Accelerator is the first development in the creation of a 200,000 square metre city centre health campus, attracting life sciences, biomedical research companies and health organisations. This will generate 5,000 high value jobs and help the city develop a thriving life science economy.”
John Tatham, partnerships director at Igloo and fund manager at the Chrysalis Fund, said: “This investment marks an important landmark for the fund demonstrating our ability to invest in projects that drive forward the city’s key strategic priorities of creating and retaining high value jobs and delivering economic growth. We’re delighted to be able to provide the loan for this development which will further bolster Liverpool’s reputation as a centre for global excellence in life sciences which represents a £1.7bn economy.”